ANIP Ani Pharmaceuticals Inc

Price (delayed)

$32.16

Market cap

$410.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$585.88M

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
Ani Pharmaceuticals's revenue has increased by 8% YoY
The gross profit has grown by 3.4% year-on-year
The company's EPS rose by 16% YoY but it fell by 11% QoQ
Ani Pharmaceuticals's net income has increased by 15% YoY but it has decreased by 11% QoQ
The debt has increased by 12% QoQ and by 8% YoY
ANIP's quick ratio is down by 7% since the previous quarter

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
12.76M
Market cap
$410.44M
Enterprise value
$585.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.13
Price to sales (P/S)
1.82
EV/EBIT
N/A
EV/EBITDA
17.16
EV/Sales
2.75
Earnings
Revenue
$213.38M
EBIT
-$10.35M
EBITDA
$34.13M
Free cash flow
$8.09M
Per share
EPS
-$1.42
Free cash flow per share
$0.67
Book value per share
$15.06
Revenue per share
$17.66
TBVPS
$24.52
Balance sheet
Total assets
$480.16M
Total liabilities
$288.24M
Debt
$204.71M
Equity
$191.92M
Working capital
$102.35M
Liquidity
Debt to equity
1.07
Current ratio
2.14
Quick ratio
1.36
Net debt/EBITDA
5.14
Margins
EBITDA margin
16%
Gross margin
59.2%
Net margin
-8.1%
Operating margin
-4.8%
Efficiency
Return on assets
-3.7%
Return on equity
-8.8%
Return on invested capital
-2.9%
Return on capital employed
-2.6%
Return on sales
-4.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
0.94%
1 week
6.84%
1 month
15.02%
1 year
16.02%
YTD
10.74%
QTD
-8.25%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$213.38M
Gross profit
$126.42M
Operating income
-$10.35M
Net income
-$17.22M
Gross margin
59.2%
Net margin
-8.1%
The company's operating income has shrunk by 68% QoQ but it rose by 38% YoY
ANIP's operating margin has dropped by 66% since the previous quarter but it is up by 44% year-on-year
The net margin has increased by 21% YoY but it has decreased by 13% QoQ
Ani Pharmaceuticals's net income has increased by 15% YoY but it has decreased by 11% QoQ

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.13
P/S
1.82
EV/EBIT
N/A
EV/EBITDA
17.16
EV/Sales
2.75
The company's EPS rose by 16% YoY but it fell by 11% QoQ
The P/B is 36% below the 5-year quarterly average of 3.3 but 6% above the last 4 quarters average of 2.0
The company's equity fell by 6% QoQ
The price to sales (P/S) is 49% lower than the 5-year quarterly average of 3.5 and 5% lower than the last 4 quarters average of 1.9
Ani Pharmaceuticals's revenue has increased by 8% YoY

Efficiency

How efficient is Ani Pharmaceuticals business performance
The company's return on sales has shrunk by 66% QoQ but it rose by 44% YoY
Ani Pharmaceuticals's ROIC has plunged by 61% from the previous quarter but it has increased by 46% YoY
The ROA has grown by 16% YoY but it has contracted by 12% from the previous quarter
The return on equity has declined by 11% since the previous quarter but it has grown by 11% year-on-year

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 67% more than its total liabilities
ANIP's total liabilities is up by 11% since the previous quarter and by 5% year-on-year
The company's current ratio rose by 8% YoY but it fell by 3.2% QoQ
The debt is 7% higher than the equity
The debt to equity has increased by 19% from the previous quarter and by 8% YoY
The debt has increased by 12% QoQ and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.